Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Evolocumab on Coronary Plaque Volume and Composition
NCT03689946Phase 3Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Mar 2019
- Primary completion
- Jan 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of evolocumab in cardiovascular disease (CVD), hyperlipidemia, sponsored by Cedars-Sinai Medical Center. Started Mar 2019; status: completed.
02
Drugs
evolocumab
03
Conditions
cardiovascular disease (CVD)hyperlipidemia
Beyond the preview
Go deeper on NCT03689946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03689946.